Capula Management LTD Vertex Pharmaceuticals Inc Put Options Transaction History

Capula Management LTD

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 13, 2024	BUY	$460.0 - $505.78 $138,000 - $151,734	300 New	300 $139,000
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $8.57 Million - $9.64 Million	-30,000 Reduced 74.81%	10,100 $2.92 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $11 Million - $12.3 Million	40,100 New	40,100 $11.6 Million
Q2 2021 Aug 13, 2021	SELL	$187.49 - $221.1 $1.78 Million - $2.1 Million	-9,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $1.55 Million - $2.07 Million	7,500 Added 375.0%	9,500 $2.25 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $2.05 Million - $2.42 Million	-8,000 Reduced 80.0%	2,000 $544,000
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $2.25 Million - $2.96 Million	10,000 New	10,000 $2.9 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $5.85 Million - $7.26 Million	-29,300 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $833,550 - $1.12 Million	-5,000 Reduced 14.58%	29,300 $6.42 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $5.7 Million - $6.42 Million	34,300 New	34,300 $5.81 Million

1,723

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

Stay updated on Capula Management LTD with notifications on news.